Log in
Enquire now
Immatics Biotechnologies

Immatics Biotechnologies

Immatics Biotechnologies is a biopharmaceutical company focused on the discovery and development of immunotherapy of cancer.

OverviewStructured DataIssuesContributors

Contents

immatics.net
immatics.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
T cell
T cell
Immunotherapy
Immunotherapy
Healthcare
Healthcare
Cancer immunotherapy
Cancer immunotherapy
Vaccine
Vaccine
Biomedical engineering
Biomedical engineering
Biopharmaceutical
Biopharmaceutical
...
Location
Germany
Germany
Houston
Houston
0
Munich
Munich
0
Tübingen
Tübingen
0
B2X
B2B
B2B
CEO
‌
Harpreet Singh
0
Founder
‌
Harpreet Singh
AngelList URL
angel.co/immatics-b...echnologies
Pitchbook URL
pitchbook.com/profiles.../11025-46
Legal Name
Immatics N.V.
Number of Employees (Ranges)
201 – 5000
Email Address
info@immatics.com0
Phone Number
+49895404150
Full Address
2201 W. Holcombe Blvd., Suite 205, Houston, Texas 770300
Paul-Ehrlich-Str. 15 72076 Tuebingen Germany0
Machtlfinger Str. 11, 81379 Munich, Germany0
Investors
L-Bank
L-Bank
NTEC
NTEC
MIG Fonds
MIG Fonds
Wellington Partners
Wellington Partners
Amgen Ventures
Amgen Ventures
‌
AT Impf
dievini Hopp Biotech Holding
dievini Hopp Biotech Holding
Grazia Equity
Grazia Equity
Founded Date
2000
Fax Number
+49 7071 5397-900
Total Funding Amount (USD)
180,092,400
Latest Funding Round Date
2017
Business Model
Commerce
Licensing
Exchange
Nasdaq
Nasdaq
CFO
‌
Arnd Christ
0
Also Known As
Immatics
Latest Funding Type
Series E
Series E
Patents Assigned (Count)
43
Wellfound ID
immatics-biotechnologies
Country
Germany
Germany
0
United States
United States
0

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
58,000,000
Ticker Symbol
IMTX
Wikidata ID
Q30256960
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Immatics Initiates Second Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers

Immatics

https://immatics.com/press-release/immatics-initiates-second-phase-i-clinical-trial-of-its-unique-actengine-platform-in-patients-with-advanced-solid-cancers.html

Web

References

Find more companies like Immatics Biotechnologies

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.